Clovis Oncology, Inc.

  1. June 05, 2023

    Shareholders, Regulators Urge Rejection Of Clovis Ch. 11 Plan

    Clovis Oncology Inc. shareholders and federal watchdogs Monday urged a Delaware bankruptcy judge to reject the company's proposed Chapter 11 liquidation plan, saying it would force shareholders to give up claims against executives without consent.

  2. December 22, 2022

    Insurers Slam Scouts Plan; FTX To Start Clawback Actions

    Insurers who didn't sign on to the Chapter 11 plan of the Boy Scouts of America slammed the $2.5 billion settlement trust in an appellate briefing, cryptocurrency exchange FTX said it will begin seeking clawback of prepetition distributions, and cosmetics giant Revlon Inc. reached a deal with creditors for a Chapter 11 plan. This is the week in bankruptcy.

  3. December 16, 2022

    Judge OKs $75M Ch. 11 Loan From Clovis Secured Lender

    A Delaware bankruptcy judge Friday ended the competition over who will provide $75 million in Chapter 11 financing for Clovis Oncology Inc., approving the offer from a secured lender and denying a request to pay the losing bidder's fees.

  4. December 15, 2022

    Clovis Oncology Ch. 11 Loan Process Down To The Wire

    A competition between two potential bankruptcy lenders for Chapter 11 debtor Clovis Oncology Inc. hit a stumbling block Thursday when one of the potential loan proposals expired, delaying approval of a $75 million financing package and taking the process up against a buyer-imposed deadline.

  5. December 14, 2022

    Two Lenders Vie For $75M Clovis Oncology Ch. 11 DIP Loan

    Competition between two potential bankruptcy financing lenders to Clovis Oncology Inc. delayed interim action on the company's proposed $75 million Chapter 11 case-financing loan in Delaware bankruptcy court on Wednesday.

  6. December 12, 2022

    Clovis Oncology Hits Ch. 11 With $754.5M Debt And Sale Plans

    Clovis Oncology Inc. took its cancer-focused biopharmaceutical business into Chapter 11 in Delaware bankruptcy court on Sunday, reporting $319 million in assets and $754.5 million in debt, with a stalking horse offer from Novartis in tow to purchase rights to a major oncology drug.